Serum vaspin and adiponectin levels in patients with prolactinoma

Basit Öğe Kaydı
dc.authoridDelibasi, Tuncay/0000-0002-5780-8209
dc.contributor.authorGinis, Zeynep
dc.contributor.authorUcar, Fatma
dc.contributor.authorErdogan, Serpil
dc.contributor.authorOzturk, Gulfer
dc.contributor.authorAkyol, Sumeyye
dc.contributor.authorErden, Gonul
dc.contributor.authorArslan, Muyesser Sayki
dc.date.accessioned2025-10-24T18:09:44Z
dc.date.available2025-10-24T18:09:44Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground: Studies investigating serum vaspin and adiponectin levels in patients with prolactinoma are inconclusive. The aim of this study was to evaluate serum vaspin and adiponectin levels in patients with prolactinoma and healthy controls. Methods: A total of 42 prolactinoma patients (Group 1, 21 patients; Group 2, 21 patients) and 30 healthy controls were enrolled in the study. Group 1 consisted of newly diagnosed patients who were never treated or had not received a dopamine agonist (DA) within 6 months prior to screening. Group 2 consisted of prolactinoma patients who were on DA treatment for at least 6 months at the time of screening. The control group (group 3) consisted of healthy controls. Results. Patients with prolactinoma had higher homeostasis model assessment of insulin resistance and lower quantitative insulin sensitivity check index values in comparison to healthy controls (p<0.001 for both). Serum levels of adiponectin and vaspin were also significantly lower in prolactinoma patients when compared to the control group (p<0.01 and p<0.001, respectively). Following adjustment for confounding factors, the respective odds ratios for prolactinoma in patients in the lower subgroup compared with those in the higher subgroup for adiponectin and vaspin were 2.733 (0.621-12.035; p>0.05) and 5.041 (1.191-21.339; p<0.05). Conclusion: This is the first study to demonstrate the presence of low vaspin levels in patients with prolactinomas. Further studies are needed to help establish the roles of vaspin and adiponectin in prolactinoma patients.
dc.identifier.doi10.3109/00365513.2015.1085080
dc.identifier.endpage24
dc.identifier.issn0036-5513
dc.identifier.issn1502-7686
dc.identifier.issue1
dc.identifier.pmid26415032
dc.identifier.scopus2-s2.0-84947862623
dc.identifier.scopusqualityQ3
dc.identifier.startpage17
dc.identifier.urihttps://doi.org/10.3109/00365513.2015.1085080
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3776
dc.identifier.volume76
dc.identifier.wosWOS:000366183000003
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofScandinavian Journal Of Clinical & Laboratory Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectAdiponectin; HOMA-IR; insulin resistance; prolactinoma; vaspin
dc.titleSerum vaspin and adiponectin levels in patients with prolactinoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu